BioGaia® Gastrus® PURE ACTION Probiotic – CDHF Certified Product
Written by: CDHF
Updated: June 25th, 2026
BioGaia® Gastrus® PURE ACTION Probiotic is certified by the Canadian Digestive Health Foundation (CDHF) for the probiotic strains Limosilactobacillus reuteri DSM 17938 and Limosilactobacillus reuteri ATCC PTA 6475, a clinically studied combination of strains shown in human studies to help relieve symptoms such as abdominal pain, bloating, and gas in people with Irritable Bowel Syndrome (IBS). It also helps promote bowel movements and regularity in adults with functional constipation and may help reduce gastrointestinal discomfort during Helicobacter pylori eradication therapy.
BioGaia is proud to partner with the Canadian Digestive Health Foundation to advance evidence-based digestive care for Canadians. As global leaders in probiotic research for more than 35 years, we develop products rooted in rigorous clinical evidence. BioGaia’s patented probiotic strains have been studied in over 270 clinical trials, making it among the most researched in the world.
One of our most innovative solutions, BioGaia® Gastrus® PURE ACTION, is a FODMAP-friendly probiotic containing two distinct and patented Limosilactobacillus reuteri strains (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), clinically shown to survive gastric transit and colonize the gut. The strains are of human origin, allowing them to thrive in the human digestive tract and work where it matters most.
Gastrus® PURE ACTION is proven to:
- Help relieve and manage symptoms associated with irritable bowel syndrome (IBS)1
- Help reduce abdominal pain, discomfort, gas, and bloating significantly in healthy adults1,2
- Help promote bowel movements/regularity in adults with functional constipation3
- Help reduce gastrointestinal antibiotic-associated side-effects4
- Help reduce side-effects during triple therapy for H. pylori infection5
BioGaia® Gastrus® PURE ACTION represents a new standard in adult digestive care- FODMAP- and allergy-friendly, clinically validated, shelf-stable, and powered by exclusive human-derived probiotic strains available only from BioGaia.
Click here for more information about BioGaia® Gastrus® PURE ACTION Probiotic
References:
1. Cruchet, S., Hirsch, S., Villa-López, D., et al. (2024). Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: A randomized controlled trial. Frontiers in Gastrointestinal Research,2, 1296048.
2. Jadrešin, O., et al. (2017). Journal of Pediatric Gastroenterology and Nutrition, 64, 925–929.
3. Ojetti, V., Ianiro, G., Tortora, A., et al. (2014). The e_ ect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: A randomized double-blind, placebo-controlled trial. Journal of Gastrointestinal and Liver Diseases, 23(4), 387–391.
4. Francavilla, R., et al. (2014). Journal of Clinical Gastroenterology, 48, 407–413.
5. Emara, M. H., Mohamed, S. Y.,& Abdel-Aziz, H. R. (2014). Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: A double-blind, placebo-controlled randomized clinical trial. Therapeutic Advances in Gastroenterology, 7(1), 4–13.
